In the past week, SUPN stock has gone down by -12.89%, with a monthly decline of -5.87% and a quarterly surge of 16.37%. The volatility ratio for the week is 2.44%, and the volatility levels for the last 30 days are 2.17% for Supernus Pharmaceuticals Inc The simple moving average for the last 20 days is -11.41% for SUPN’s stock, with a simple moving average of 2.93% for the last 200 days.
Is It Worth Investing in Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Right Now?
The price-to-earnings ratio for Supernus Pharmaceuticals Inc (NASDAQ: SUPN) is 345.30x, which is above its average ratio. Moreover, the 36-month beta value for SUPN is 0.89. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SUPN is 52.76M and currently, short sellers hold a 12.42% of that float. On September 11, 2024, SUPN’s average trading volume was 521.95K shares.
SUPN) stock’s latest price update
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has experienced a decline in its stock price by -8.96 compared to its previous closing price of 33.49. However, the company has seen a fall of -12.89% in its stock price over the last five trading days. globenewswire.com reported 2024-08-28 that ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.
Analysts’ Opinion of SUPN
Jefferies, on the other hand, stated in their research note that they expect to see SUPN reach a price target of $45, previously predicting the price at $44. The rating they have provided for SUPN stocks is “Buy” according to the report published on January 03rd, 2023.
Jefferies gave a rating of “Buy” to SUPN, setting the target price at $44 in the report published on December 01st of the previous year.
SUPN Trading at -2.32% from the 50-Day Moving Average
After a stumble in the market that brought SUPN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.97% of loss for the given period.
Volatility was left at 2.17%, however, over the last 30 days, the volatility rate increased by 2.44%, as shares sank -8.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.05% upper at present.
During the last 5 trading sessions, SUPN fell by -11.97%, which changed the moving average for the period of 200-days by +12.40% in comparison to the 20-day moving average, which settled at $34.28. In addition, Supernus Pharmaceuticals Inc saw 5.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SUPN starting from TAMI TILLOTSON MARTIN, who proposed sale 4,000 shares at the price of $29.02 back on Aug 02 ’24. After this action, TAMI TILLOTSON MARTIN now owns shares of Supernus Pharmaceuticals Inc, valued at $116,074 using the latest closing price.
TAMI TILLOTSON MARTIN, the Former Officer of Supernus Pharmaceuticals Inc, proposed sale 3,100 shares at $29.31 during a trade that took place back on Aug 01 ’24, which means that TAMI TILLOTSON MARTIN is holding shares at $90,856 based on the most recent closing price.
Stock Fundamentals for SUPN
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.78 for the gross margin
The net margin for Supernus Pharmaceuticals Inc stands at 0.01. The total capital return value is set at 0.04. Equity return is now at value 0.56, with 0.40 for asset returns.
Based on Supernus Pharmaceuticals Inc (SUPN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 3.87. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -8.51.
Currently, EBITDA for the company is 98.26 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 2.65. The receivables turnover for the company is 4.13for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.91.
Conclusion
To wrap up, the performance of Supernus Pharmaceuticals Inc (SUPN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
